The effect of sevoflurane postconditioning on cardioprotection against ischemia-reperfusion injury in rabbits.
Sevoflurane postconditioning is a potential clinical measure to protect myocardial. This experiment was designed to investigate the efficacy of sevoflurane postconditioning against ischemia-reperfusion injury. A total of 132 Japanese White Rabbits were enrolled into this study. They were underwent 15-, 30-, or 60-min left anterior descending coronary (LAD) artery occlusion, respectively. At the end of LAD artery occlusion, they randomly received a 5-min inhalation of air (control group), 1% sevoflurane (1% sev group), 2% sevoflurane (2% sev group), 4% sevoflurane (4% sev group) or an IV bolus injection of 5 mg/kg of NIM811 [a specific inhibitor of mitochondrial permeability transition pores (mPTP)]. Infarct size was determined after 2 h of reperfusion (triphenyltetrazolium chloride straining, percentage of risk area). The infarct sizes were significantly (P < 0.05) reduced after 15 min ischemia (5.5 ± 3.3%, 5.8 ± 3.6% vs. 20.3 ± 6.9% for 2% sev, 4% sev vs. control, respectively) and 30 min ischemia (23.5 ± 5.0%, 20.7 ± 5.9% vs. 50.9 ± 10.2%, for 2% sev, 4% sev vs. control, respectively; P < 0.05). However, it had no effect on infarct size after 60 min ischemia (64.1 ± 5.9%, 62.3 ± 7.6% vs. 72.7 ± 9.2% for 2% sev, 4% sev vs. control, respectively, P > 0.05).The efficacy of sevoflurane postconditioning gradually weakened with increasing ischemia duration and disappears after 60 min ischemia in rabbits in vivo.
Department of Anesthesiology, FuWai Cardiovascular Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beilishi Road, Xicheng District, Beijing, 100037, People's Republic of China.
Dong
D
Chen
Bo
B
Cheng
Hai-Yan
HY
Zhou
Li-Huan
LH
Li
D000818:Animals; D002316:Cardiotonic Agents / Q000494:pharmacology*; D005260:Female; D006352:Heart Ventricles / Q000187:drug effects / Q000473:pathology / Q000503:physiopathology; D006439:Hemodynamics / Q000187:drug effects; D057775:Ischemic Postconditioning; D008297:Male; D008738:Methyl Ethers / Q000494:pharmacology*; D009203:Myocardial Infarction / Q000097:blood / Q000150:complications / Q000473:pathology / Q000503:physiopathology; D015428:Myocardial Reperfusion Injury / Q000097:blood / Q000150:complications / Q000503:physiopathology / Q000517:prevention & control*; D009929:Organ Size / Q000187:drug effects; D011817:Rabbits; D012307:Risk Factors; D000077149:Sevoflurane; D014336:Troponin / Q000097:blood; D016277:Ventricular Function, Left / Q000187:drug effects
D002316:Cardiotonic Agents; D008738:Methyl Ethers; D014336:Troponin; D000077149:Sevoflurane